Table 4.
Cumulative gross tumor incidence in vaccinated birds challenged by HNLC302 or Md5 strains calculated at 91 days post-infection (dpi).
| Vaccines * | Strains | Total Birds | Deaths | Survivals | Total | |||
|---|---|---|---|---|---|---|---|---|
| Tumors /Deaths |
Tumor Incidence (%) |
Tumors /Survivals |
Tumor Incidence (%) |
Tumors | Tumor Incidence (%) |
|||
| CEF | HN302 | 37 | 13/24 | 54.17 | 13/13 | 100.00 | 26/37 | 70.27 |
| Md5 | 36 | 18/29 | 62.07 | 7/7 | 100.00 | 25/36 | 69.44 | |
| HVT | HN302 | 36 | 2/4 | 50.00 | 20/32 | 62.50 ab | 22/36 | 61.11 b |
| Md5 | 35 | 3/8 | 37.50 | 8/27 | 29.63 ab | 11/35 | 31.43 b | |
| CVI988 | HN302 | 37 | 8/12 | 66.67 b | 15/25 | 60.00 ab | 23/37 | 62.16 b |
| Md5 | 38 | 0/11 | 0.00 ab | 5/28 | 17.86 ab | 5/38 | 13.16 ab | |
* Equal volume of mock CEF suspension serves as vaccine negative controls. a Indicates significant difference between HVT- or CVI988-vaccinated groups and CEF-mock groups challenged by the same virus. b Indicates significant difference between HNLH302 and Md5 viruses in the same vaccination group.